ABSI ABSCI CORP

Absci to Report Business Updates and Third Quarter 2024 Financial and Operating Results on November 12, 2024

Absci to Report Business Updates and Third Quarter 2024 Financial and Operating Results on November 12, 2024

VANCOUVER, Wash. and NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the third quarter before market open on Tuesday, November 12, 2024.

Absci management will webcast a corresponding conference call beginning at 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time to discuss its business developments, financial and operating results, and outlook.

Live audio of the webcast will be available on the company’s investor relations website at: investors.absci.com. The webcast will be archived and available for replay after the event.

About Absci

is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed candidates to wet lab-validated candidates in as little as six weeks. Absci’s headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit and follow us on LinkedIn (), X (Twitter) (), and.

Investor Contact

Alex Khan

VP, Finance & Investor Relations

Media Contact



EN
15/10/2024

Underlying

ABSIABSCI CORP

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ABSCI CORP

 PRESS RELEASE
Free
ABSI ABSCI CORP

Absci to Participate in the 36th Annual Piper Sandler Healthcare Confe...

Absci to Participate in the 36th Annual Piper Sandler Healthcare Conference VANCOUVER, Wash. and NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming 36th Annual Piper Sandler Healthcare Conference in New York, NY. Absci’s Founder & CEO Sean McClain is scheduled to participate in a panel discussion titled “The Promise of AI in Drug Development” on Thursday, December 5th at 2:00 p.m. Eastern Time. Interested parties may contact their Piper Sandler r...

November 21, 2024 1 EN
 PRESS RELEASE
Free
ABSI ABSCI CORP

Absci Reports Business Updates and Third Quarter 2024 Financial and Op...

Absci Reports Business Updates and Third Quarter 2024 Financial and Operating Results Successfully delivered AI de novo designed antibody sequences to AstraZeneca, fulfilling first milestone under collaboration Entered into collaboration with Twist Bioscience to design a novel antibody using generative AI VANCOUVER, Wash. and NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today reported financial and operating results for the quarter ended September 30, 2024. "The recent progress we have made across our po...

November 12, 2024 1 EN
 PRESS RELEASE
Free
ABSI ABSCI CORP

Absci to Host R&D Day on December 12, 2024

Absci to Host R&D Day on December 12, 2024 VANCOUVER, Wash. and NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will host its 2024 R&D Day on Thursday, December 12th in New York City. The program will begin at 9:00 a.m. Eastern Time and feature presentations from members of Absci’s leadership team as well as guest speakers, followed by an interactive Q&A session. The program is expected to conclude at approximately 12:00 p.m. Eastern Time. Interested parties may access a live and ...

November 7, 2024 1 EN
 PRESS RELEASE
Free
ABSI ABSCI CORP

Absci and Twist Bioscience Collaborate to Design Novel Antibody using ...

Absci and Twist Bioscience Collaborate to Design Novel Antibody using Generative AI Collaboration brings together Absci’s Generative AI drug creation platform with Twist’s DNA synthesis platform to accelerate the design of a novel therapeutic antibody VANCOUVER, Wash. and SOUTH SAN FRANCISCO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: ABSI) a data-first generative AI drug creation company, and (NASDAQ: TWST) a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today unveiled a collaboration to design a novel the...

October 31, 2024 1 EN
 PRESS RELEASE
Free
ABSI ABSCI CORP

Absci to Participate in Upcoming Investor Conferences

Absci to Participate in Upcoming Investor Conferences VANCOUVER, Wash. and NEW YORK, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the following upcoming investor conferences. Truist Securities BioPharma Symposium (New York, NY)Hosting 1x1 meetings on Thursday, November 7 Guggenheim Securities Inaugural Healthcare Innovation Conference (Boston, MA)Fireside chat on Monday, November 11 at 10:00 a.m. Eastern Time / 7:00 a.m. Pacific Time, and hosting 1x1 meetings UB...

October 24, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch